- Reports first quarter 2026 total revenue of
$8.0 million , representing 11% growth compared to the first quarter of 2025- Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems in the first quarter of 2025
- First quarter 2026 product revenue increased 36% year-over-year; consumable revenue increased over 30%
- First quarter 2026 recurring revenue increased 28% year-over-year; comprised 63% of total revenue
- First quarter 2026 product gross margin percentage increased 15-percentage points; consumable gross margin increased 33-percentage points
- Advanced strategic collaboration with
MilliporeSigma with execution of Services Agreement - Reaffirms full year 2026 total revenue guidance range of
$37.0 million to$41.0 million including a range of 30 to 38 Growth Direct system placements - Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with Q4 2026 exit rate in mid-20% range
"Our first quarter results reflect strong and consistent execution across the business," said
First Quarter Financial Results
Total revenue for the first quarter of 2026 increased 11.1% to
Total cost of revenue was
Total operating expenses increased by 17.9% to
Net loss for the first quarter of 2026 was
Cash, cash equivalents, short-term investments, and restricted cash were approximately
Full Year 2026 Outlook
The Company is reaffirming its full year 2026 total revenue guidance range of
Company Presentation Available
The Company has posted an updated presentation, titled Rapid Micro Biosystems Corporate Presentation -
This presentation is available at https://investors.rapidmicrobio.com/news-and-events/presentations
Webcast Details
The Company will host a conference call before the market opens today,
About
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2026 total revenue, gross margin, number of Growth Direct placements and system validations; and the Company's growth outlook in future periods.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company's ability to fulfill customer orders on its anticipated timelines or at all; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the
Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) | |||||||
| Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Revenue: | |||||||
| Product revenue | $ | 5,578 | $ | 4,101 | |||
| Service revenue | 2,424 | 3,104 | |||||
| Total revenue | 8,002 | 7,205 | |||||
| Cost of revenue: | |||||||
| Cost of product revenue | 6,025 | 5,029 | |||||
| Cost of service revenue | 1,606 | 1,772 | |||||
| Total cost of revenue | 7,631 | 6,801 | |||||
| Gross margin | 371 | 404 | |||||
| Operating expenses: | |||||||
| Research and development | 3,359 | 3,624 | |||||
| Sales and marketing | 3,422 | 2,751 | |||||
| General and administrative | 7,442 | 5,690 | |||||
| Total operating expenses | 14,223 | 12,065 | |||||
| Loss from operations | (13,852 | ) | (11,661 | ) | |||
| Other income (expense): | |||||||
| Interest income | 256 | 466 | |||||
| Interest expense | (639 | ) | (12 | ) | |||
| Other expense, net | (32 | ) | (49 | ) | |||
| Total other income (expense), net | (415 | ) | 405 | ||||
| Loss before income taxes | (14,267 | ) | (11,256 | ) | |||
| Income tax expense | 8 | 7 | |||||
| Net loss | $ | (14,275 | ) | $ | (11,263 | ) | |
| Net loss per share — basic and diluted | $ | (0.31 | ) | $ | (0.26 | ) | |
| Weighted average common shares outstanding — basic and diluted | 45,433,800 | 43,993,359 | |||||
Unaudited Condensed Consolidated Balance Sheets (in thousands) | |||||
2026 | 2025 | ||||
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 13,815 | $ | 20,030 | |
| Short-term investments | 9,134 | 18,266 | |||
| Accounts receivable | 6,367 | 3,134 | |||
| Inventory, net | 17,447 | 17,593 | |||
| Prepaid expenses and other current assets | 2,463 | 2,145 | |||
| Total current assets | 49,226 | 61,168 | |||
| Property and equipment, net | 8,770 | 8,972 | |||
| Right-of-use assets | 3,838 | 4,109 | |||
| Other long-term assets | 245 | 319 | |||
| Restricted cash | 284 | 284 | |||
| Total assets | 62,363 | 74,852 | |||
| Liabilities and Stockholders’ Equity | |||||
| Current liabilities: | |||||
| Accounts payable | $ | 4,670 | $ | 4,139 | |
| Accrued expenses and other current liabilities | 6,495 | 8,316 | |||
| Deferred revenue | 6,634 | 4,734 | |||
| Lease liabilities, short-term | 1,320 | 1,298 | |||
| Total current liabilities | 19,119 | 18,487 | |||
| Lease liabilities, long-term | 3,337 | 3,674 | |||
| Notes payable, net | 19,053 | 18,902 | |||
| Warrant liability | 116 | 186 | |||
| Other long-term liabilities | 340 | 397 | |||
| Total liabilities | 41,965 | 41,646 | |||
| Total stockholders’ equity | 20,398 | 33,206 | |||
| Total liabilities and stockholders’ equity | $ | 62,363 | $ | 74,852 | |
| RAPIDMICRO BIOSYSTEMS, INC. Unaudited Cash, Cash Equivalents and Investments (in thousands) | |||||
2026 | 2025 | ||||
| Cash and cash equivalents | $ | 13,815 | $ | 20,030 | |
| Short-term investments | 9,134 | 18,266 | |||
| Restricted cash | 284 | 284 | |||
| Cash, cash equivalents, investments and restricted cash | $ | 23,233 | $ | 38,580 | |
Investor ContactMichael Beaulieu , CFAVice President, Investor Relations and Corporate Communicationsinvestors@rapidmicrobio.comMedia Contactmedia@rapidmicrobio.com
